Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...

Massachusetts-based Boston Scientific generates most of its revenue from sales of its heart devices, such as pacemakers and stents. It also makes equipment to diagnose and treat a range of ...

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot ...

Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral interventions. MedSurg segment revenues increased 10.3% to $1.48 billion (10.4% operationally and 7.7 ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

(Reuters) -Boston Scientific increased its annual profit forecast on Wednesday, fueled by strong demand for its cardiac implants, but temporarily halted a pivotal heart equipment study citing ...

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the consensus estimate of $4.04 billion. Sales ...